News and Insights from Our Multidisciplinary Team of Experts
February 19, 2019 – Machine learning, which provides the ability to learn a task from data (without the need of being programmed explicitly), is a key component of any Pathology AI (Artificial Intelligence) system. There are many different approaches in machine...
IntroductionJanuary 14, 2019 – Study of the minuscule is not possible without aid of an instrument because the human retina does not possess sufficient angular resolution to discern microscopic detail at the focal lengths achievable by its natural lens. Thus the...
December 3, 2018 – People may think that an automated artificial intelligence (AI) system for pathology that achieves a performance of 90 percent outperforms pathologists. However, pathologists are using microscopes for a task that includes complex computations –...
Westminster, CO — November 13, 2018 — CIOReview has named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful...
Westminster, CO – November 8, 2018 — Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in...
November 4, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven pathology solutions at the Digital Pathology Association’s 2018 Pathology Visions conference, November 4 – 6, 2018, in San Diego, CA.
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS/POSTERS
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for pathology AI lies in personalized medicine with big data. Better characterization of the patient...
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc. (Flagship) with the 2018 Global Technology Innovation Award. Each year,...
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory...
EVENTS
View our Webcast Recording on TissueInsight®: Realizing the Clinical Diagnostic Potential of Digital Pathology. This recorded webcast will benefit pathologists and oncologists, attending physicians, image analysts, and those interested in digital pathology. Attendees...
SITC 2021 Annual Meeting:Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking place both virtually and in person November 10-14, 2021 at the Walter E. Washington Convention Center in...
Recently Flagship hosted a webcast on Tissue-Based CDx Development and Image Analysis in a Regulated space. Our discussion stems from the fact that the United States Food and Drug Administration (FDA) requires comprehensive analytical validation and clinical...